You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

ViiV Healthcare @ EAS 2017

ViiV Healthcare held a webinar to discuss data for dolutegravir in the real-world setting, focusing on switching and tolerability in clinical practice. Additionally, an update was given on results from the Positive Perspectives Survey – an international patient survey of over 1,000 patients exploring their opinions on healthcare, stigma and treatment satisfaction.

Chapter 1: EU patient experience and views on antiretroviral treatment: Findings from the Positive Perspectives Study

Presented by Andrew Murungi, Medical Affairs Operations Director, ViiV Healthcare.

Chapter 2: Meta-analysis of safety for DTG versus other ARVs in randomised trials: Analysis of cardiovascular, CNS and IRIS endpoints

Presented by Dr. Annemiek de Ruiter, Senior Global Medical Director, ViiV Healthcare

Chapter 3: New data from EACS 2017: Latest dolutegravir clinical data

Presented by Prof. Jan Van Lunzen, Senior Global Medical Affairs Director, ViiV Healthcare

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.

Triumeq

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.